The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Dr. Tolaney Discusses Patient Selection for Platinum-Based Therapy in TNBC

Sara M. Tolaney, MD, MPH
Published Online:8:50 PM, Mon August 24, 2015

Sara M. Tolaney, MD, MPH, physician, instructor in medicine, Harvard Medical School, medical oncologist, Dana-Farber Cancer Institute, discusses patient selection for platinum-based therapy in triple-negative breast cancer (TNBC).
Tolaney believes the standard of care will remain standard chemotherapy for triple-negative disease. However, she feels it is important to learn which patients could benefit from the additional platinum-based therapy. 
A common question is whether or not a patient with a BRCA mutation should receive platinum-based therapy. In previous studies, the pathological complete response rates were high for patients with this mutation, so it may be beneficial for this therapy to be incorporated into BCRA carriers in the future.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.